PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
The cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway detects cytosolic DNA to activate innate immune responses. Poly(ADP-ribose) polymerase inhibitors (PARPi) selectively target cancer cells with DNA repair deficiencies such as those caused by BRCA1 mutations or ERCC1 defects. Using isogenic cell lines and patient-derived samples, we showed that ERCC1-defective non-small cell lung cancer (NSCLC) cells exhibit an enhanced type I IFN transcriptomic signature and that low ERCC1 expression correlates with increased lymphocytic infiltration. We demonstrated that clinical PARPi, including olaparib and rucaparib, have cell-autonomous immunomodulatory properties in ERCC1-defective NSCLC and BRCA1-defective triple-negative breast cancer (TNBC) cells. Mechanistically, PARPi generated cytoplasmic chromatin fragments with characteristics of micronuclei; these were found to activate cGAS/STING, downstream type I IFN signaling, and CCL5 secretion. Importantly, these effects were suppressed in PARP1-null TNBC cells, suggesting that this phenotype resulted from an on-target effect of PARPi on PARP1. PARPi also potentiated IFN-γ-induced PD-L1 expression in NSCLC cell lines and in fresh patient tumor cells; this effect was enhanced in ERCC1-deficient contexts. Our data provide a preclinical rationale for using PARPi as immunomodulatory agents in appropriately molecularly selected populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“various FDA-approved and experimental PARP inhibitors have been shown to drive robust type I IFN secretion downstream of increased cytosolic availability of ssDNA or micronuclei (DNAcontaining structures generally formed by faulty mitoses) in a variety of tumors, including (but not limited to) BRCA1- and BRCA2-deficient neoplasms (Chabanon et al., 2019; Ding et al., 2018; Pantelidou et al., 2019;”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chabanon et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, the administration of PARP inhibitors has been associated with PD-L1 upregulation in various cancer cells regardless of BRCA1/2 status, presumably as a consequence of type I IFN or IFNG signaling (Chabanon et al., 2019; Jiao et al., 2017; Sen et al., 2019; Shen et al., 2019).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chabanon et al., 2019
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · cited 2×
“While various DDR defects have been shown to critically contribute to the accumulation of mutations in the tumor genome, only some of them have proven their predictive value as biomarkers of response to anti-PD-(L)1 therapy (6, 45).”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 2×
“Both ERCC1 and BRCA1 defects confer sensitivity to platinum-based therapy (26, 27) and PARP inhibitors (PARPi) (28, 29), and while PARPi have demonstrated their efficacy in advanced BRCA-deficient breast cancers (30), these”
BackgroundSelf-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 1×
“Very recent impressive results of large phase III trials in NSCLC have reported unprecedented improvements in overall survival and progression free survival when using anti-programmed death receptor 1 or -ligand 1 (anti-PD-(L)1) in first-line therapy (1, 2).”
BackgroundGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · cited 12×
“Other DNA repair defects, such as BRCA1/2 mutations have been found enriched in ICI responders (12).”
BackgroundInfluentialGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · cited 1×
“Other DNA repair defects, such as BRCA1/2 mutations have been found enriched in ICI responders (12).”
BackgroundOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294 · cited 1×
“Both ERCC1 and BRCA1 defects confer sensitivity to platinum-based therapy (26, 27) and PARP inhibitors (PARPi) (28, 29), and while PARPi have demonstrated their efficacy in advanced BRCA-deficient breast cancers (30), these”
BackgroundClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065 · cited 1×
“However, a simple correlation between DNA repair defects-induced genomic instability, TMB and response to ICI cannot be claimed (5), as tumor heterogeneity (13) and other determinants of response also play a role that, importantly, seems to be independent from TMB in response to ICI (14, 15).”
BackgroundNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · cited 2×
“Very recent impressive results of large phase III trials in NSCLC have reported unprecedented improvements in overall survival and progression free survival when using anti-programmed death receptor 1 or -ligand 1 (anti-PD-(L)1) in first-line therapy (1, 2).”
BackgroundPARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880 · cited 1×
“We further hypothesized that PARPi, which do not only inhibit the catalytic activity of PARP1, but also trap PARP1 onto the DNA, causing stalled replication forks and subsequent double-strand breaks (DSBs) (34), might specifically favor the formation of CCF and in turn trigger cGAS/STING signaling in ERCC1-defective t…”
BackgroundSelf-citationRegulation and function of the cGAS–STING pathway of cytosolic DNA sensing
Chen, Q., Sun, L., & Chen, Z. J. (2016) · Nature Immunology · doi:10.1038/ni.3558 · Cited by 2,333 · cited 4×
“6 Another interface between DDR and immunogenicity, which has recently generated particular attention in immuno-oncology, is the cyclic GMP-AMP synthase / stimulator of interferon genes (cGAS/STING) pathway (16).”
BackgroundInfluentialMitochondrial DNA stress primes the antiviral innate immune response
West, A. P., Khoury-Hanold, W., Staron, M., Tal, M. C., Pineda, C. M., Lang, S. M., Bestwick, M., Duguay, B. A., Raimundo, N., MacDuff, D. A., et al. (2015) · Nature · doi:10.1038/nature14156 · Cited by 1,975
cGAS surveillance of micronuclei links genome instability to innate immunity
Mackenzie, K. J., Carroll, P., Martin, C.-A., Murina, O., Fluteau, A., Simpson, D. J., Olova, N., Sutcliffe, H., Rainger, J. K., Leitch, A., et al. (2017) · Nature · doi:10.1038/nature23449 · Cited by 1,752 · cited 6×
“This extends and is consistent with previous publications, which reported activation of cGAS/STING by micronuclei either following ionizing radiation (19, 20) or Sphase-specific chemotherapies (17, 18), and further described PARPi-mediated induction of IFN signals (notably increased STAT1 phosphorylation) in BRCA1-def…”
BackgroundResultInfluentialDNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., Taranchon, E., Filipits, M., Pirker, R., Popper, H. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,727
Self-citationLoi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., Rouas, G., Francis, P., Crown, J. P. A., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,632 · cited 8×
“Importantly, these effects were suppressed in PARP1-null TNBC cells, suggesting that this phenotype resulted from an on-target effect of PARPi on PARP1.”
BackgroundInfluentialMitotic progression following DNA damage enables pattern recognition within micronuclei
Harding, S. M., Benci, J. L., Irianto, J., Discher, D. E., Minn, A. J., & Greenberg, R. A. (2017) · Nature · doi:10.1038/nature23470 · Cited by 1,508 · cited 4×
“This extends and is consistent with previous publications, which reported activation of cGAS/STING by micronuclei either following ionizing radiation (19, 20) or Sphase-specific chemotherapies (17, 18), and further described PARPi-mediated induction of IFN signals (notably increased STAT1 phosphorylation) in BRCA1-def…”
BackgroundResultInfluentialMcCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310 · cited 1×
“For example, BRCA1, BRCA2, ATM or MSH2 (mutated in 5%, 6%, 9% and 3% of NSCLC cases, respectively (49)) have also been associated with PARPi sensitivity and type I IFN signature (50-53).”
BackgroundSelf-citationDistinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics · doi:10.1038/ng.3564 · Cited by 1,200 · cited 1×
“For example, BRCA1, BRCA2, ATM or MSH2 (mutated in 5%, 6%, 9% and 3% of NSCLC cases, respectively (49)) have also been associated with PARPi sensitivity and type I IFN signature (50-53).”
BackgroundConsensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119
Hellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega, F., Ahuja, A., Ni, A., Novik, J. B., Mangarin, L. M. B., Abu-Akeel, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.018 · Cited by 1,095 · cited 1×
“High TMB has also been correlated with better response to ICI in melanoma (9) and NSCLC (2, 10, 11).”
BackgroundCancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · cited 1×
“Considering the critical immunogenic and lympho-attractant properties of these chemokines (33), this suggested that ERCC1 deficiency might contribute to the establishment of cancer-cell autonomous immunity in NSCLC cells.”
BackgroundSelf-citationCyclic GMP-AMP Synthase Is an Innate Immune Sensor of HIV and Other Retroviruses
Gao, D., Wu, J., Wu, Y.-T., Du, F., Aroh, C., Yan, N., Sun, L., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1240933 · Cited by 992 · cited 1×
“It can detect free DNA, arising from reverse-transcription of endogenous retroviruses (55) or mitochondrial DNA instability (56), and micronuclei, which arise from genomic instability and display chromatinlike structures, sometimes surrounded by a fragile lamin B1 membrane (19).”
BackgroundPARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 912 · cited 2×
“Because platinum-sensitivity is a relevant phenotypical biomarker of sensitivity to PARPi (27), this suggests that PARPi – which are much better tolerated and do not have severe bone marrow toxicity – might represent an interesting alternative or complement (in the maintenance setting) to platinum-based chemotherapy i…”
BackgroundSelf-citationGettinger, S., Horn, L., Jackman, D., Spigel, D., Antonia, S., Hellmann, M., Powderly, J., Heist, R., Sequist, L. V., Smith, D. C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0412 · Cited by 738 · cited 1×
“Likewise, remarkable 5-year survival rates of 16% have recently been reported in this disease (3), highlighting the ability of these agents to provide long-term tumor control.”
BackgroundIFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., Baba, T., Konishi, I., & Mandai, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.101 · Cited by 725
Härtlova, A., Erttmann, S. F., Raffi, F. A., Schmalz, A. M., Resch, U., Anugula, S., Lienenklaus, S., Nilsson, L. M., Kröger, A., Nilsson, J. A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.012 · Cited by 716 · cited 1×
“For example, BRCA1, BRCA2, ATM or MSH2 (mutated in 5%, 6%, 9% and 3% of NSCLC cases, respectively (49)) have also been associated with PARPi sensitivity and type I IFN signature (50-53).”
BackgroundDNA Damage and Repair Biomarkers of Immunotherapy Response
Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D'Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 645 · cited 1×
“While various DDR defects have been shown to critically contribute to the accumulation of mutations in the tumor genome, only some of them have proven their predictive value as biomarkers of response to anti-PD-(L)1 therapy (6, 45).”
BackgroundBRCA1 dysfunction in sporadic basal-like breast cancer
Turner, N. C., Reis-Filho, J. S., Russell, A. M., Springall, R. J., Ryder, K., Steele, D., Savage, K., Gillett, C. E., Schmitt, F. C., Ashworth, A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210014 · Cited by 573
Self-citationcGAS is essential for the antitumor effect of immune checkpoint blockade
Wang, H., Hu, S., Chen, X., Shi, H., Chen, C., Sun, L., & Chen, Z. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621363114 · Cited by 563 · cited 12×
“Other DNA repair defects, such as BRCA1/2 mutations have been found enriched in ICI responders (12).”
BackgroundInfluentialTeo, M. Y., Seier, K., Ostrovnaya, I., Regazzi, A. M., Kania, B. E., Moran, M. M., Cipolla, C. K., Bluth, M. J., Chaim, J., Al-Ahmadie, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7740 · Cited by 544 · cited 13×
“Other DNA repair defects, such as BRCA1/2 mutations have been found enriched in ICI responders (12).”
BackgroundInfluentialNiedernhofer, L. J., Odijk, H., Budzowska, M., van Drunen, E., Maas, A., Theil, A. F., de Wit, J., Jaspers, N. G. J., Beverloo, H. B., Hoeijmakers, J. H. J., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5776-5787.2004 · Cited by 492 · cited 1×
“ERCC1 deficiency has been associated with increased mutation frequency and genomic instability in mice (46), an observation that is consistent with the known roles of ERCC1 in processes that ensure chromosomal stability and maintenance of genome integrity, such as the interstrand crosslink DNA repair pathway (47) and…”
BackgroundParkes, E. E., Walker, S. M., Taggart, L. E., McCabe, N., Knight, L. A., Wilkinson, R., McCloskey, K. D., Buckley, N. E., Savage, K. I., Salto-Tellez, M., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw199 · Cited by 462
Pettitt, S. J., Krastev, D. B., Brandsma, I., Dréan, A., Song, F., Aleksandrov, R., Harrell, M. I., Menon, M., Brough, R., Campbell, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03917-2 · Cited by 449 · cited 4×
“To do this, we used recently described isogenic series derived from the BRCA1-mutant TNBC SUM149 cell line (35, 36).”
BackgroundMethodInfluentialSelf-citationSpranger, S., Luke, J. J., Bao, R., Zha, Y., Hernandez, K. M., Li, Y., Gajewski, A. P., Andrade, J., & Gajewski, T. F. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609376113 · Cited by 399 · cited 12×
“Other DNA repair defects, such as BRCA1/2 mutations have been found enriched in ICI responders (12).”
BackgroundInfluentialImmune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Mehnert, J. M., Panda, A., Zhong, H., Hirshfield, K., Damare, S., Lane, K., Sokol, L., Stein, M. N., Rodriguez-Rodriquez, L., Kaufman, H. L., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84940 · Cited by 380 · cited 1×
“The best illustrations of this are probably mismatchrepair deficient tumors (6), and POLE/POLD1-mutated endometrial carcinoma and glioblastoma (7, 8), which are highly sensitive to ICI, likely due to their increased neoantigen repertoire.”
BackgroundERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
Friboulet, L., Olaussen, K. A., Pignon, J.-P., Shepherd, F. A., Tsao, M.-S., Graziano, S., Kratzke, R., Douillard, J.-Y., Seymour, L., Pirker, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214271 · Cited by 371 · cited 4×
“To address this hypothesis in a relatively unbiased fashion, we first used RNA sequencing (RNA-Seq) to profile the transcriptome of isogenic ERCC1-defective and wildtype A549 NSCLC cells (31, 32).”
BackgroundMethodInfluentialSelf-citationPrognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer
Brambilla, E., Le Teuff, G., Marguet, S., Lantuejoul, S., Dunant, A., Graziano, S., Pirker, R., Douillard, J.-Y., Le Chevalier, T., Filipits, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0970 · Cited by 349 · cited 1×
“Interestingly, high TILs levels correlate with improved survival following neoadjuvant therapy in TNBC (42) – an observation that was also made in some NSCLC series in the adjuvant setting (43).”
BackgroundSelf-citationPARP-1 Regulates Chromatin Structure and Transcription through a KDM5B-Dependent Pathway
Krishnakumar, R., & Kraus, W. L. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.08.014 · Cited by 326 · cited 1×
“As PARPi have been reported to modulate histone PARylation and chromatin structure (37), thereby potentially promoting transcription of retro-elements, we further confirmed the presence of chromatin (i.”
BackgroundJohanns, T. M., Miller, C. A., Dorward, I. G., Tsien, C., Chang, E., Perry, A., Uppaluri, R., Ferguson, C., Schmidt, R. E., Dahiya, S., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0575 · Cited by 289 · cited 1×
“The best illustrations of this are probably mismatchrepair deficient tumors (6), and POLE/POLD1-mutated endometrial carcinoma and glioblastoma (7, 8), which are highly sensitive to ICI, likely due to their increased neoantigen repertoire.”
BackgroundTeo, M. Y., Bambury, R. M., Zabor, E. C., Jordan, E., Al-Ahmadie, H., Boyd, M. E., Bouvier, N., Mullane, S. A., Cha, E. K., Roper, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2520 · Cited by 280 · cited 1×
“recently reported that somatic DDR alterations that were associated with improved clinical outcomes in platinum-treated patients with advanced urothelial carcinoma (54), also correlated with longer progression-free survival and overall survival upon anti-PD-(L)1 therapy (15).”
BackgroundResearch Advances in How the cGAS-STING Pathway Controls the Cellular Inflammatory Response
Wan, D., Jiang, W., & Hao, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00615 · Cited by 270
Chopra, N., Tovey, H., Pearson, A., Cutts, R., Toms, C., Proszek, P., Hubank, M., Dowsett, M., Dodson, A., Daley, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16142-7 · Cited by 259
Self-citationMutational Landscape and Sensitivity to Immune Checkpoint Blockers
Chabanon, R. M., Pedrero, M., Lefebvre, C., Marabelle, A., Soria, J.-C., & Postel-Vinay, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0903 · Cited by 230 · cited 2×
“Indeed, DDR defects result in genomic instability and increased tumor mutational burden (TMB), which has been linked – at least in some cases – to better outcome upon ICI treatment (5).”
BackgroundSelf-citationErdal, E., Haider, S., Rehwinkel, J., Harris, A. L., & McHugh, P. J. (2017) · Genes & Development · doi:10.1101/gad.289769.116 · Cited by 227 · cited 2×
“This extends and is consistent with previous publications, which reported activation of cGAS/STING by micronuclei either following ionizing radiation (19, 20) or Sphase-specific chemotherapies (17, 18), and further described PARPi-mediated induction of IFN signals (notably increased STAT1 phosphorylation) in BRCA1-def…”
BackgroundResultSelf-citationSchwartz, E. K., & Heyer, W.-D. (2011) · Chromosoma · doi:10.1007/s00412-010-0304-7 · Cited by 198
ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
Williamson, C. T., Muzik, H., Turhan, A. G., Zamò, A., O'Connor, M. J., Bebb, D. G., & Lees-Miller, S. P. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0872 · Cited by 193 · cited 1×
“For example, BRCA1, BRCA2, ATM or MSH2 (mutated in 5%, 6%, 9% and 3% of NSCLC cases, respectively (49)) have also been associated with PARPi sensitivity and type I IFN signature (50-53).”
BackgroundReplication Stress, DNA Damage, Inflammatory Cytokines and Innate Immune Response
Ragu, S., Matos-Rodrigues, G. E., & López, B. S. (2020) · Genes · doi:10.3390/genes11040409 · Cited by 142
The potential of exploiting DNA-repair defects for optimizing lung cancer treatment
Postel-Vinay, S. C., Vanhecke, E., Olaussen, K. A., Lord, C. J., Ashworth, A., & Soria, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.3 · Cited by 132 · cited 1×
“Excision repair cross-complementation group 1 (ERCC1) deficiency is the most frequent DDR defect in NSCLC and occurs in 30-50% of cases (23).”
BackgroundSelf-citationPostel-Vinay, S. C., Bajrami, I., Friboulet, L., Elliott, R. J. R., Fontebasso, Y., Dorvault, N., Olaussen, K. A., André, F., Soria, J., Lord, C. J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.311 · Cited by 114 · cited 6×
“PARPi generate CCF in an ERCC1 defect- and cell cycle-dependent manner As previously reported (28), A549-ERCC1 cells display enhanced sensitivity to PARPi when compared to A549-ERCC1 cells, an effect that we reconfirmed in short-term survival assays (Figure 3A).”
BackgroundMethodResultInfluentialSelf-citationXu, Y., Diao, L., Chen, Y., Liu, Y., Wang, C. Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt011 · Cited by 97 · cited 1×
“The tumor suppressor protein BRCA1 is also frequently defective in triplenegative breast cancer (TNBC), either following germline mutation or somatic alteration (mutation or epigenetic silencing) (24, 25).”
BackgroundAdam, J., Louvet, E., Sourisseau, T., Dorvault, N., Bernard, M., Maingot, E., Faivre, L., Cassin-Kuo, M.-S., Boissier, E., Dessoliers, M.-C., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000257 · Cited by 96
Self-citationMelton, D. W., Ketchen, A.-M., Núñez, F., Bonatti-Abbondandolo, S., Abbondandolo, A., Squires, S., & Johnson, R. T. (1998) · Journal of Cell Science · doi:10.1242/jcs.111.3.395 · Cited by 95
Modeling Therapy Resistance in BRCA1/2 -Mutant Cancers
Dréan, A., Williamson, C. T., Brough, R., Brandsma, I., Menon, M. R., Konde, A., García-Murillas, I., Pemberton, H. N., Frankum, J. R., Rafiq, R., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0098 · Cited by 90 · cited 3×
“To do this, we used recently described isogenic series derived from the BRCA1-mutant TNBC SUM149 cell line (35, 36).”
BackgroundMethodSelf-citationWang, K., Wang, J., Wei, F., Zhao, N., Yang, F., & Ren, X. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00456 · Cited by 79 · cited 1×
“To assess the specificity of the observed effect, we evaluated the membrane expression of Toll-like receptor 4, an immune-related cellsurface marker which has been described to be positively correlated with PD-L1 expression in NSCLC samples (41).”
BackgroundCan innate immune system targets turn up the heat on 'cold' tumours?
Mullard, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.264 · Cited by 64 · cited 1×
“Further, cGAS recently appeared to be an essential mediator of the anti-tumor effects of ICI (21), and identification of cGAS/STING activators has become an intense research area, with several ongoing phase 1 trials evaluating such molecules (22).”
BackgroundElevation of interferon beta-inducible proteins in ataxia telangiectasia cells.
Siddoo-Atwal, C., Haas, A. L., & Rosin, M. P. (1996) · PubMed · Cited by 50
Advances and challenges in immunotherapy of small cell lung cancer
Guo, H., Li, L., & Cui, J. (2020) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2020.01.13 · Cited by 32
DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade
Touat, M., Sourisseau, T., Dorvault, N., Chabanon, R. M., Garrido, M., Morel, D., Krastev, D. B., Bigot, L., Adam, J., Frankum, J. R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci90277 · Cited by 32 · cited 2×
“ERCC1 status in these tumors was evaluated by immunohistochemistry (IHC) as previously described (32) and TILs were assessed using a morphology-based coverage score.”
MethodSelf-citationGenomic Features of Response to Combination Immunotherapy in Lung Cancer
Früh, M., & Peters, S. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.005 · Cited by 31
Research works printed but not linked: 1
- Robillard L. Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 PD-L1 inhibition in a syngenic BRCA2 mutant ovarian cancer model. Proceedings of the AACR. 2017;58(pt A):3650. Accessed January 7, 2019.
Cited by
Molecular mechanisms and cellular functions of cGAS–STING signalling
Hopfner, K.-P., & Hornung, V. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0244-x · Cited by 2,052
DNA sensing by the cGAS–STING pathway in health and disease
Motwani, M., Pesiridis, S., & Fitzgerald, K. A. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0151-1 · Cited by 1,467
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119
Detection of immunogenic cell death and its relevance for cancer therapy
Fucikova, J., Kepp, O., Kasikova, L., Petroni, G., Yamazaki, T., Liu, P., Zhao, L., Spisek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03221-2 · Cited by 1,138
Inflammatory microenvironment remodelling by tumour cells after radiotherapy
McLaughlin, M., Patin, E. C., Pedersen, M., Wilkins, A., Dillon, M. T., Melcher, A. A., & Harrington, K. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0246-1 · Cited by 883
Metadata
- Authors
- Chabanon, R. M., Muirhead, G., Krastev, D. B., Adam, J., Morel, D., Garrido, M., Lamb, A., Hénon, C., Dorvault, N., Rouanne, M., Marlow, R., Bajrami, I., Cardeñosa, M. L., Konde, A., Besse, B., Ashworth, A., Pettitt, S. J., Haider, S., Marabelle, A., Tutt, A. N. J., Soria, J.-C., Lord, C. J., & Postel-Vinay, S.
- Affiliations
- Université Paris-Sud (FR)
- Breast Cancer Now (GB)
- Institute of Cancer Research (GB)
- Inserm (FR)
- Sage Bionetworks (US)
- King's College London (GB)
- University of California, San Francisco (US)
- ORCID
- Chabanon, Roman M.
- Krastev, Dragomir B.
- Adam, Julien
- Morel, Daphné
- Garrido, Marlène
- Lamb, Andrew
- Dorvault, Nicolas
- Rouanne, Mathieu
- Marlow, Rebecca
- Bajrami, Ilirjana
- Besse, Benjamin
- Ashworth, Alan
- Pettitt, Stephen J.
- Haider, Syed
- Marabelle, Aurélien
- Tutt, Andrew N.J.
- Soria, Jean-Charles
- Lord, Christopher J.
- Postel-Vinay, Sophie
- Venue
- Journal of Clinical Investigation
- Published
- 2019-02-11
- Volume
- 129
- Issue
- 3
- Pages
- 1211-1228
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6391116
- OpenAlex
- W2908418801
- Cited by
- 332
- References
- 62
- Citations by year
- 2026: 31 · 2025: 36 · 2024: 39 · 2023: 45 · 2022: 43 · 2021: 61 · 2020: 54 · 2019: 22
- FWCI
- 12.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- AstraZeneca
- Sanofi
- Merck KGaA
- Les Laboratories Pierre Fabre
- Fondation Philanthropia
- Cancer Research UK (14276, 25237, 24439)
- Institut National de la Santé et de la Recherche Médicale (INCa-DGOS-INSERM_12551)
- Institut National Du Cancer (INCa-DGOS-INSERM-12551)
- Institut Gustave-Roussy
- Direction Générale de l’offre de Soins
- Servier
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- PARP inhibitors, non-small cell lung cancer, triple-negative breast cancer, cGAS-STING pathway, cytosolic DNA sensing, type I interferon, PARP1, micronuclei, RANTES, PD-L1 expression, lymphocyte infiltration, olaparib, rucaparib, DNA repair deficiency
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, A549 Cells, STING Protein, Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase, Carcinoma, Non-Small-Cell Lung, DNA-Binding Proteins, Endonucleases, Female, Humans, Interferon-gamma, Lung Neoplasms, Membrane Proteins, Nucleotidyltransferases, BRCA1 Protein, B7-H1 Antigen, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.